RedTalks #2 Saison 4: IDH2 mutation in T-Cell Lymphoma : new mouse model to investigate IDH2 mutation impact
CALYM Institute launches its RedTalks, a Series of scientific Webinars
Date : Thursday, November 9th 2023 – 6:00 PM (CET)
- Dr. Julie LECA, postdoctoral researcher at the Cancer initiation and tumor cell identity (CITI) at the Lyon Cancer Research Center (Centre Léon Bérard)
- Dr. Sylvain CARRAS, University Hospital Practitioner at CHU Grenoble Alpes
- Pr. Philippe Gaulard, Professor of Pathology at the Mondor Biomedical Research Institute AP-HP in Créteil (France)
We are delighted to welcome Dr. Julie LECA, postdoctoral researcher at the Cancer initiation and tumor cell identity (CITI) at the Lyon Cancer Research Center (Centre Léon Bérard)
Dr. Julie Leca completed her master’s degree in immunology at the Faculty of Sciences of Aix-Marseille University in Luminy, Marseille. She then started her PhD in October 2011 at Marseille’s Cancerology Research Center (CRCM) in Dr. Juan Iovanna’s team and under the supervision of Dr. Richard Tomasini. Dr. Iovanna’s team focused on the study of pancreatic cancer, and Dr. Tomasini’s group studied the molecular dialogue between transformed pancreatic cells and components of the stroma. After completion of her doctoral studies in 2016, Dr. Leca joined Pr. Tak Mak’s lab at the Princess Margaret Cancer Center in Toronto, Canada for a 7-year-long post-doctorate position.
Dr. Leca’s post-doctorate work focused on the different IDH mutations in the context of hematological diseases such as Angioimmunoblastic T-cell lymphomas (AITL) and Acute Myeloid Leukemias (AML). Her main subject was the study of the cooperation of TET2 and IDH2 mutations in AITL, which was carried out in collaboration with Pr. Philippe Gaulard’s team and Dr. François Lemonnier in Paris.
In October 2023, Dr. Leca returned to France and joined Dr. Veronique Maguer Satta’s lab at Lyon’s Cancerology Research Center (CRCL). Her team’s work is dedicated to exploring the BMP signaling pathway in the biology of stem cells (breast cancer or AML) and their interactions with their micro-environment, using their innovative and newly developed 3D model of the medullary niche.
Angioimmunoblastic T cell lymphoma (AITL) is a peripheral T cell lymphoma that originates from T follicular helper (Tfh) cells and exhibits a prominent tumor microenvironment (TME). IDH2 and TET2 mutatio poorly understood. This RedTalk topic will be highlighting the synergy of these two mutations in modulating T Follicular Helper cell functional interaction with the AITL microenvironment.